JAC Advance Access published online on February 10, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki014
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Bloomsbury Institute of Intensive Care Medicine, Department of Medicine, University College London, London, UK
* To whom correspondence should be addressed. Objectives: To determine the pharmacokinetic characteristics of linezolid and teicoplanin in critically ill patients. Patients and methods: Serum was collected frequently during day 0 and then pre- and 1 h post-dose on days 1, 2, 3, 5, 7 and every third day thereafter during treatment. Serum linezolid concentrations were analysed using HPLC. Serum teicoplanin levels were analysed by fluorescence polarization immunoassay. Results: A two-compartment model was required to characterize linezolid pharmacokinetics (n=28) and account for the accumulation seen after multiple dosing. The estimated clearance was 0.049 ±0.016 L/h/kg (±s.e.m. of estimate). At steady state (dosing interval 12 h), linezolid serum concentrations exceeded the breakpoint of 4 mg/L for 10.88 h (95% CI 10.09-11.66) after a 600 mg dose with an AUC/MIC of 92.4 (95% CI 57.2-127.7). Teicoplanin was best described by a two-compartment model (n=26). The clearance was 4.97±1.58 L/h. Serum levels exceeded the breakpoint of 4 mg/L for the entire dosing interval in all subjects (400 mg dose every 12 h) with an AUC/MIC of 399.3 (95% CI 329.6-469.0). However, only four of 14 exceeded trough serum concentrations of 10 mg/L. For both agents, trough levels were similar in those who survived and those who died. Conclusions: Linezolid dosage at 600 mg every 12 h was adequate in the critically ill without need for adjustment for renal function. For teicoplanin, further study is needed to confirm if a trough of 10 mg/L is associated with a higher rate of cure than 5 mg/L. If so, serum drug assays would be needed to ensure a therapeutic level.
Received July 13, 2004
Revised November 4, 2004
Accepted December 8, 2004
Original article
Pharmacokinetic studies of linezolid and teicoplanin in the critically ill
2 Departments of Clinical Microbiology,, London UK
3 Departments ofPharmacy, University College London Hospitals, London, UK
4 School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
5 Facultad de Farmacia, Universidad de Valencia, Valencia, Spain
6 Department of Microbiology, Southmead Hospital, Bristol, UK
7 Intensive Care Unit, UK
8 Department of Medical Microbiology, Royal Free Hospital, London, UK
A. Peter R. Wilson, E-mail: peter.wilson{at}uclh.nhs.uk
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Abe, K. Chiba, B. Cirincione, T. H. Grasela, K. Ito, and T. Suwa Population Pharmacokinetic Analysis of Linezolid in Patients With Infectious Disease: Application to Lower Body Weight and Elderly Patients J. Clin. Pharmacol., September 1, 2009; 49(9): 1071 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Luna, D. A. Bruno, J. Garcia-Morato, K. C. Mann, J. Risso Patron, J. Sagardia, R. Absi, M. Garcia Bottino, D. Marchetti, A. Famiglietti, et al. Effect of Linezolid Compared With Glycopeptides in Methicillin-Resistant Staphylococcus aureus Severe Pneumonia in Piglets Chest, June 1, 2009; 135(6): 1564 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Plock, C. Buerger, C. Joukhadar, S. Kljucar, and C. Kloft Does Linezolid Inhibit Its Own Metabolism? Population Pharmacokinetics As a Tool to Explain the Observed Nonlinearity in Both Healthy Volunteers and Septic Patients Drug Metab. Dispos., October 1, 2007; 35(10): 1816 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Myrianthefs, S. L. Markantonis, K. Vlachos, M. Anagnostaki, E. Boutzouka, D. Panidis, and G. Baltopoulos Serum and Cerebrospinal Fluid Concentrations of Linezolid in Neurosurgical Patients Antimicrob. Agents Chemother., December 1, 2006; 50(12): 3971 - 3976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Buerger, N. Plock, P. Dehghanyar, C. Joukhadar, and C. Kloft Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2455 - 2463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Charlesworth, M. Warner, D. M. Livermore, and A. P. R. Wilson Comparison of four methods for detection of teicoplanin resistance in methicillin-resistant Staphylococcus aureus J. Antimicrob. Chemother., July 1, 2006; 58(1): 186 - 189. [Abstract] [Full Text] [PDF]
|
|